RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA™ in Advanced Solid Tumors Jun 22, 2016
RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA™ for IBS-D Jun 21, 2016
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016 Jun 3, 2016
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association – European Dialysis & Transplant Association Congress (ERA-EDTA) May 25, 2016
RepliCel Life Sciences conducts formal consultation review with Japan’s PMDA and receives unprecedented review fee reduction Apr 26, 2016
RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trials Apr 21, 2016
The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium Apr 19, 2016
RepliCel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates Apr 9, 2016
RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement Apr 7, 2016
RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection Mar 9, 2016
